Distribution Agreement for Human Cell Culture Products in India, International Stem Cell Corporation (ISCO.OB)
ISCO.OB’s Lifeline Cell Technology® (Lifeline) and Sristi Biosciences have entered into a distribution agreement for the Lifeline® brand of human cell culture products in India.
ISCO.OB’s Lifeline specializes in development, manufacture and distribution of primary human cells and media and growth factors for optimized culturing of cells, including stem cells. These products are being requested by customers internationally, including in India, which represents one of the fastest growing markets for products of this kind. The group sells over 75 standardized products directly and via its distributors in the US and abroad. It also engages in customized product development for its largest customers.
ISCO recently announced the beginning of a collaboration on its human corneal tissue, CytoCor™, with leading Indian eye hospital and research center, Sankara Nethralaya, and Letter of Intent with Insight BioVentures India (IBVI) to seek funding and establishment of development and manufacturing operations for ISCO’s research and pharmaceutical products in India (ISCO India), including the Lifeline products and CytoCor.
‘The Lifeline distribution agreement with Sristi Biosciences is central to ISCO’s international expansion. Besides facilitating commercialization of the Lifeline products in India, Sristi Biosciences’ cell therapy development, regulatory and manufacturing expertise will be important as ISCO and IBVI seek to establish ISCO India with cost-efficient development and manufacturing of research and pharmaceutical products for the Indian and broader Asian markets,’ says Brian Lundstrom, ISCO’s President.
